-
Can Ketamine Treat Alcohol Addiction? The Awakn Approach
Monday, October 10, 2022 - 10:24am | 893(Part three of a four-part series) As for ketamine-assisted therapy, biotech psychedelics company Awakn Life Sciences (OTC: AWAKNF) offers two distinct protocols. One is called KARE (Ketamine in the Reduction of Alcoholic Relapse) and is specific to alcohol use disorder, while the other, KAP (...
-
Can Ketamine Treat Alcohol Addiction? Clinics & Hospitals In Europe And North America Are Already Doing It
Friday, September 30, 2022 - 9:44am | 697(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public discussion and reform. Each compound is proven to have specific characteristics,...
-
Battling With Booze? Here's A Deeper Look At Ketamine for Alcohol Use Disorder
Saturday, September 10, 2022 - 12:32pm | 1207This article by Elisabetta Fato was originally published on Microdose and appears here with permission. In the last decades, there has been a growing interest in psychedelics for the treatment of mood and behavioral disorders, among which are substance use disorders. Lately, the psychedelic...
-
Promising Finding For Alcohol Addiction: A Solution Just Might Be In Magic Mushrooms
Thursday, August 25, 2022 - 1:19pm | 920A recent clinical study led by NYU Langone found that psilocybin, the psychoactive ingredient in magic mushrooms, reduced heavy drinking by 83%, compared with a 51% reduction among those who received an antihistamine placebo. Psychedelic treatment for alcoholism became popular in the...
-
Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder
Tuesday, August 16, 2022 - 1:23pm | 420Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd. (OTCQB: RVLWF), through which Revitalist will treat patients suffering from...
-
Awakn Life Sciences: Business And Corporate Update For Psychedelics Biotech
Friday, July 15, 2022 - 6:13pm | 382Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has just published its business and corporate updates. Besides researching, developing and commercializing therapeutics to treat substance and behavioral addictions, Awakn’s near-term focus is on the Alcohol Use...
-
High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA
Thursday, May 26, 2022 - 1:37pm | 312The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage. This will allow Clearmind to move forward in the...
-
Top 5 Most Influential Psychedelic Studies
Tuesday, March 29, 2022 - 5:08pm | 1743This article was originally published on Psychedelic Spotlight and appears here with permission. While psychedelic studies now number in the thousands since Western research began in the 1950s, we unpack five of the most important in recent years as psychedelics are on the cusp of becoming...
-
Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder
Friday, January 21, 2022 - 6:56am | 278Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD). The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (WHO)...
-
FDA Denies Adial Pharma's Fast Track Request For AD04 in Alcohol Use Disorder
Friday, June 25, 2021 - 9:02am | 227Adial Pharmaceuticals Inc (NASDAQ: ADIL) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder has been denied at this time. The FDA stated that the Company has not yet demonstrated that the product shows potential, and the...
-
MediciNov's MN-166 Reduces Odds Of Heavy Drinking by 45% After 14 Days Of Treatment
Monday, June 21, 2021 - 7:20am | 267MediciNov Inc (NASDAQ: MNOV) has announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature's Translational Psychiatry. The trial was funded by the Center for Study of Opioid Receptors and Drugs of Abuse. The...
-
Tonix Plans Regulatory Filing To Kick Off Study Of Alcohol Use Disorder Drug
Thursday, November 21, 2019 - 10:40am | 286Shares of nano-cap biotech Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) were volatile Thursday morning following an announcement concerning its pre-investigational new drug application meeting with the U.S Food and Drug Administration. Following the receipt of the minutes of the Type B, pre-...